AEON Biopharma Inc
AEON.WS
AEON.WS was delisted on the 26th of April, 2024.
50 hedge funds and large institutions have $6.98M invested in AEON Biopharma Inc in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 8 closing their positions.
9% less funds holding
Funds holding: 55 → 50 (-5)
17% less capital invested
Capital invested by funds: $8.42M → $6.98M (-$1.44M)
29% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 7
63% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Parallax Volatility Advisers
San Francisco,
California
|
+$153K |
| 2 |
AC
Aristeia Capital
Greenwich,
Connecticut
|
+$138K |
| 3 |
CF
Cantor Fitzgerald
New York
|
+$22K |
| 4 |
Nomura Holdings
Tokyo,
Japan
|
+$12.3K |
| 5 |
CC
Centiva Capital
New York
|
+$6.88K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$87K |
| 2 |
Blackstone Inc
New York
|
-$85K |
| 3 |
ICMH
Integrity Capital Management (HK)
Central,
Hong Kong
|
-$35K |
| 4 |
RA
Ramius Advisors
New York
|
-$35K |
| 5 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$25K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
51
Blackstone Inc
New York
| – | -$85K | -166,666 | Closed |
|
|
ICMH
52
Integrity Capital Management (HK)
Central,
Hong Kong
| – | -$35K | -69,514 | Closed |
|
|
RA
53
Ramius Advisors
New York
| – | -$35K | -68,879 | Closed |
|
|
WAM
54
Wolverine Asset Management
Chicago,
Illinois
| – | -$25K | -50,076 | Closed |
|
|
CL
55
CSS LLC
Chicago,
Illinois
| – | -$18K | -35,282 | Closed |
|
|
NAM
56
Nexpoint Asset Management
Dallas,
Texas
| – | -$7K | -13,333 | Closed |
|
|
EC
57
EJF Capital
Arlington,
Virginia
| – | -$5K | -10,000 | Closed |
|
|
CS
58
Clear Street
New York
| – | +$94 | +227 | New |
|
AEON.WS Hedge Fund Activity: Q1 2022 in Review
50 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in AEON Biopharma Inc (AEON.WS) for Q1 2022, worth a combined $6.98M — down 17% from $8.42M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of AEON.WS and 3 opened new positions — a net loss of 5 holders — while 7 trimmed existing stakes and 5 added.
The largest buyer was Parallax Volatility Advisers, adding an estimated $153K. The largest seller was UBS O'Connor, exiting entirely with an estimated $87K sold.
- 50 institutional investors held AEON Biopharma Inc (AEON.WS) as of Q1 2022, down from 55 in Q4 2021.
- Funds reported $6.98M of AEON Biopharma Inc stock for Q1 2022, down 17% quarter-over-quarter.
- 3 funds opened new AEON Biopharma Inc positions in Q1 2022 and 8 closed out, a net change of -5 holders.
- The largest AEON Biopharma Inc buyer in Q1 2022 was Parallax Volatility Advisers, an estimated $153K added.
- The largest AEON Biopharma Inc seller in Q1 2022 was UBS O'Connor, an estimated $87K sold.
Based on aggregated 13F filings for Q1 2022.